$109 Million is the total value of Opus Point Partners Management, LLC's 67 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 23.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIB | Buy | PROSHARES TR | $6,969,000 | +69.9% | 130,500 | +53.5% | 6.38% | +109.7% |
| MRK | MERCK & CO INC | $5,364,000 | +0.9% | 83,700 | 0.0% | 4.91% | +24.5% | |
| XBI | Sell | SPDR SERIES TRUSTs&p biotech | $5,017,000 | -44.3% | 65,000 | -50.0% | 4.60% | -31.3% |
| XBI | New | SPDR SERIES TRUSTput | $5,017,000 | – | 65,000 | +100.0% | 4.60% | – |
| BMY | BRISTOL MYERS SQUIBB CO | $5,015,000 | +2.5% | 90,000 | 0.0% | 4.59% | +26.5% | |
| ALXN | ALEXION PHARMACEUTICALS INCcall | $4,258,000 | +0.3% | 35,000 | 0.0% | 3.90% | +23.8% | |
| AZN | ASTRAZENECA PLCsponsored adr | $4,091,000 | +9.5% | 120,000 | 0.0% | 3.75% | +35.1% | |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $3,916,000 | -15.2% | 49,095 | -45.5% | 3.59% | +4.6% |
| IBB | New | ISHARES TRput | $3,876,000 | – | 12,500 | +100.0% | 3.55% | – |
| IBB | Sell | ISHARES TRnasdq biotec etf | $3,876,000 | -47.1% | 12,500 | -50.0% | 3.55% | -34.7% |
| PFE | PFIZER INC | $3,772,000 | -1.8% | 112,300 | 0.0% | 3.46% | +21.1% | |
| GSK | GLAXOSMITHKLINE PLCsponsored adr | $2,587,000 | +2.3% | 60,000 | 0.0% | 2.37% | +26.2% | |
| BMY | BRISTOL MYERS SQUIBB COcall | $2,508,000 | +2.5% | 45,000 | 0.0% | 2.30% | +26.5% | |
| ALKS | Sell | ALKERMES PLC | $2,471,000 | -49.8% | 42,623 | -49.4% | 2.26% | -38.1% |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $2,448,000 | -34.2% | 18,994 | -44.1% | 2.24% | -18.7% |
| BIB | New | PROSHARES TRput | $2,270,000 | – | 42,500 | +100.0% | 2.08% | – |
| INCY | Sell | INCYTE CORP | $2,245,000 | -52.3% | 17,832 | -49.4% | 2.06% | -41.2% |
| IONS | Sell | IONIS PHARMACEUTICALS INC | $2,232,000 | -29.6% | 43,867 | -44.4% | 2.04% | -13.1% |
| REGN | Sell | REGENERON PHARMACEUTICALS | $2,226,000 | -28.5% | 4,532 | -43.6% | 2.04% | -11.8% |
| MTD | Sell | METTLER TOLEDO INTERNATIONAL | $2,115,000 | -38.6% | 3,594 | -50.0% | 1.94% | -24.1% |
| QGEN | Sell | QIAGEN NV | $1,904,000 | -41.2% | 56,796 | -49.2% | 1.74% | -27.4% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $1,900,000 | -56.5% | 97,199 | -47.8% | 1.74% | -46.3% |
| CELG | Sell | CELGENE CORP | $1,863,000 | -46.9% | 14,344 | -49.1% | 1.71% | -34.4% |
| SGEN | Sell | SEATTLE GENETICS INC | $1,816,000 | -58.4% | 35,093 | -49.5% | 1.66% | -48.7% |
| RXDX | New | IGNYTA INC | $1,765,000 | – | 170,500 | +100.0% | 1.62% | – |
| ILMN | Sell | ILLUMINA INC | $1,720,000 | -48.1% | 9,915 | -49.0% | 1.58% | -36.0% |
| AMGN | Sell | AMGEN INC | $1,691,000 | -46.9% | 9,821 | -49.4% | 1.55% | -34.4% |
| BIIB | Sell | BIOGEN INC | $1,568,000 | -49.7% | 5,777 | -49.3% | 1.44% | -37.9% |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $1,522,000 | -47.3% | 16,762 | -49.1% | 1.39% | -35.0% |
| AGIO | Sell | AGIOS PHARMACEUTICALS INC | $1,517,000 | -54.8% | 29,482 | -48.6% | 1.39% | -44.2% |
| CLVS | Sell | CLOVIS ONCOLOGY INC | $1,404,000 | -26.5% | 15,000 | -50.0% | 1.29% | -9.3% |
| LLY | LILLY ELI & COcall | $1,235,000 | -2.1% | 15,000 | 0.0% | 1.13% | +20.7% | |
| PCRX | Sell | PACIRA PHARMACEUTICALS INC | $1,193,000 | -47.7% | 25,000 | -50.0% | 1.09% | -35.4% |
| ALXN | Sell | ALEXION PHARMACEUTICALS INC | $1,159,000 | -48.9% | 9,526 | -49.1% | 1.06% | -36.9% |
| LOXO | New | LOXO ONCOLOGY INC | $1,107,000 | – | 13,800 | +100.0% | 1.01% | – |
| LABU | Buy | DIREXION SHS ETF TRsp biotch bl new | $1,009,000 | +142.5% | 16,002 | +83.4% | 0.92% | +199.0% |
| PRTK | Sell | PARATEK PHARMACEUTICALS INC | $964,000 | -37.4% | 40,000 | -50.0% | 0.88% | -22.7% |
| KPTI | New | KARYOPHARM THERAPEUTICS INC | $905,000 | – | 100,000 | +100.0% | 0.83% | – |
| AXSM | Sell | AXSOME THERAPEUTICS INC | $734,000 | -29.5% | 133,500 | -50.0% | 0.67% | -13.1% |
| GILD | GILEAD SCIENCES INCcall | $706,000 | +4.0% | 10,000 | 0.0% | 0.65% | +28.4% | |
| TSRO | Sell | TESARO INC | $699,000 | -54.6% | 5,000 | -50.0% | 0.64% | -44.0% |
| KITE | Sell | KITE PHARMA INC | $613,000 | +31.5% | 5,915 | -0.3% | 0.56% | +62.4% |
| JUNO | Sell | JUNO THERAPEUTICS INC | $537,000 | +34.2% | 17,970 | -0.3% | 0.49% | +65.7% |
| MDCO | Sell | MEDICINES CO | $532,000 | -61.1% | 14,000 | -50.0% | 0.49% | -52.1% |
| CKPT | New | CHECKPOINT THERAPEUTICS INC | $530,000 | – | 117,760 | +100.0% | 0.49% | – |
| MYGN | Sell | MYRIAD GENETICS INC | $527,000 | +34.1% | 20,414 | -0.3% | 0.48% | +65.4% |
| ADMS | Sell | ADAMAS PHARMACEUTICALS INC | $525,000 | -50.0% | 30,000 | -50.0% | 0.48% | -38.3% |
| XON | Sell | INTREXON CORP | $442,000 | +21.1% | 18,345 | -0.4% | 0.40% | +49.4% |
| SNR | Sell | NEW SR INVT GROUP INC | $421,000 | -50.7% | 41,850 | -50.0% | 0.39% | -39.1% |
| AXGT | AXOVANT SCIENCES LTD | $404,000 | +55.4% | 17,425 | 0.0% | 0.37% | +91.7% | |
| RARE | Sell | ULTRAGENYX PHARMACEUTICAL IN | $382,000 | -53.8% | 6,157 | -49.5% | 0.35% | -43.0% |
| AKBA | Sell | AKEBIA THERAPEUTICS INC | $302,000 | -22.0% | 21,009 | -50.0% | 0.28% | -3.5% |
| GRFS | Sell | GRIFOLS S Asp adr rep b nvt | $272,000 | -34.3% | 12,885 | -41.3% | 0.25% | -18.9% |
| Q | Sell | QUINTILES IMS HOLDINGS INC | $261,000 | -35.6% | 2,921 | -41.9% | 0.24% | -20.6% |
| CRL | Sell | CHARLES RIV LABS INTL INC | $259,000 | -35.1% | 2,562 | -42.3% | 0.24% | -19.9% |
| LGND | Sell | LIGAND PHARMACEUTICALS INC | $257,000 | -34.8% | 2,113 | -43.2% | 0.24% | -19.5% |
| TECH | Sell | BIO TECHNE CORP | $248,000 | -35.6% | 2,112 | -44.3% | 0.23% | -20.6% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $238,000 | -40.2% | 5,175 | -43.7% | 0.22% | -26.1% |
| GILD | Sell | GILEAD SCIENCES INC | $230,000 | -41.0% | 3,256 | -43.2% | 0.21% | -27.0% |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $220,000 | – | 29,934 | +100.0% | 0.20% | – |
| ICPT | Sell | INTERCEPT PHARMACEUTICALS IN | $220,000 | -41.3% | 1,820 | -45.0% | 0.20% | -27.3% |
| HRTX | Sell | HERON THERAPEUTICS INC | $220,000 | -53.8% | 15,874 | -50.0% | 0.20% | -42.8% |
| CFRX | Sell | CONTRAFECT CORP | $218,000 | -59.6% | 150,000 | -50.0% | 0.20% | -50.1% |
| AVXS | Sell | AVEXIS INC | $205,000 | -46.1% | 2,500 | -50.0% | 0.19% | -33.3% |
| REPH | Sell | RECRO PHARMA INC | $177,000 | -59.9% | 25,231 | -50.0% | 0.16% | -50.5% |
| PGNX | Sell | PROGENICS PHARMACEUTICALS IN | $148,000 | -64.0% | 21,782 | -50.0% | 0.14% | -55.4% |
| SCYX | Sell | SCYNEXIS INC | $119,000 | -67.7% | 66,608 | -50.0% | 0.11% | -60.1% |
| MCRB | Exit | SERES THERAPEUTICS INC | $0 | – | -14,000 | -100.0% | -0.12% | – |
| STML | Exit | STEMLINE THERAPEUTICS INC | $0 | – | -20,595 | -100.0% | -0.13% | – |
| BIVV | Exit | BIOVERATIV INC | $0 | – | -5,587 | -100.0% | -0.23% | – |
| ALDR | Exit | ALDER BIOPHARMACEUTICALS INC | $0 | – | -17,858 | -100.0% | -0.28% | – |
| UTHR | Exit | UNITED THERAPEUTICS CORP DEL | $0 | – | -2,756 | -100.0% | -0.28% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -11,130 | -100.0% | -0.28% | – |
| LBIO | Exit | LION BIOTECHNOLOGIES INC | $0 | – | -53,157 | -100.0% | -0.29% | – |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INC | $0 | – | -25,000 | -100.0% | -0.73% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
| ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
| VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
| ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
| SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
| ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
| INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
| NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
| REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
| CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-17 |
| 13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.